Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings

Affiliations

• ¹ Penn State University, Department of Medicine and Pediatrics, Hershey, Pa. Electronic address: tcraig@pennstatehealth.psu.edu.
• ² AARA Research Center, Dallas, Texas.
• ³ University of Milan, Department of Medicine, Milan, Italy.
• ⁴ Department of Medicine, UC San Diego, La Jolla, Calif.
• ⁵ University of Cincinnati College of Medicine and Bernstein Clinical Research Center, LLC, Cincinnati, Ohio.
• ⁶ Clinical Research Center of Alabama, Birmingham, Ala.
• ⁷ Allergy and Asthma Clinical Research, Inc., Walnut Creek, Calif.
• ⁸ Division of Rheumatology, Allergy & Immunology, Department of Medicine, University of California, San Diego, La Jolla, Calif.
• ⁹ Medical Research of Arizona, Scottsdale, Ariz.
• ¹⁰ Massachusetts General Hospital, Department of Medicine, Boston, Mass.
• ¹¹ Marycliff Clinical Research, Spokane, Wash.
• ¹² Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER U754), Madrid, Spain.
• ¹³ Hungarian Angioedema Reference Center, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
• ¹⁴ CSL Behring, Marburg, Germany.
• ¹⁵ CSL Behring, King of Prussia, Pa.
• ¹⁶ Department of Immunology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.